Adalimumab levels detected in cord blood and infants exposed in utero, researchers report
Sunday, May 8, 2011 - 18:30
in Health & Medicine
Adalimumab, a drug often prescribed for women with Crohn's disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn's bloodstream for at least three months, researchers have found.